Guardant Health Q1: Revenue Surges, Profitability Nears

Guardant Healths Q1 2026 report shows a significant revenue boost of 48.3% to $301.7M, surpassing Wall Street estimates by 8.4%. Full-year guidance is raised to $1.31B, topping analyst predictions. The companys liquid biopsy technology, used for non-invasive cancer detection, drives impressive growth, with a 33.8% annualized revenue increase. Investors reacted positively, pushing the stock up 6.5% to $98.50 and boosting the market cap to $12.23B. Adjusted EPS loss narrowed to $0.45, better than expected, and operating margins improved from -54.6% to -40.2%. Analysts forecast 25.4% revenue growth and narrowing losses in the next year, indicating Guardants progress towards profitability. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/baab4286054f23dc